This confirms the specific prognostic contribution of this biomarker, possibly indicating cognitive impairment, and suggests that prognostic estimates based on different blood biomarkers, with p-tau181 mainly reflecting LMN degeneration and NfL expressing the overall disease severity, may have an added value in ALS patients. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.